CapsoVision (NASDAQ:CV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of CapsoVision (NASDAQ:CV) to a hold rating in a research note released on Saturday.

CV has been the subject of a number of other research reports. Roth Capital set a $7.00 price target on shares of CapsoVision in a research note on Tuesday, November 4th. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research note on Friday, November 14th. Zacks Research raised CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (e)” rating on shares of CapsoVision in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CapsoVision has an average rating of “Moderate Buy” and a consensus target price of $6.00.

CapsoVision Stock Down 12.9%

Shares of CV stock opened at $6.10 on Friday. The firm has a market cap of $285.72 million and a P/E ratio of -2.79. The business’s 50 day moving average is $8.24. CapsoVision has a 52 week low of $3.43 and a 52 week high of $15.37.

CapsoVision (NASDAQ:CV) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $3.54 million during the quarter.

Institutional Investors Weigh In On CapsoVision

An institutional investor recently bought a new position in CapsoVision stock. Citadel Advisors LLC acquired a new stake in shares of CapsoVision, Inc. (NASDAQ:CV) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned approximately 0.05% of CapsoVision at the end of the most recent quarter.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.